Heron Ther­a­peu­tics launch­es patent suit against My­lan over po­ten­tial gener­ic for chemo-re­lat­ed nau­sea

Last year
Pharma
Law

Two phar­ma­cy ben­e­fit man­ag­er stud­ies find in­creas­ing fees and de­clin­ing opin­ions as House con­sid­ers ac­tion

Last year
Pharma
Marketing

Mar­ket­ingRx roundup: Ab­bott teams with Weight­Watch­ers for glu­cose mon­i­tor­ing; Ha­le­on’s Advil starts ‘pain ...

Last year
Pharma
Marketing

Q&A: Gilead pub­lic af­fairs chief on new strat­e­gy, Tik­Tok, and why the com­pa­ny won’t ‘keep do­ing things the same ...

Last year
Pharma
Marketing

Rentschler names Benedikt von Braun­muehl as CEO; Catal­ent grabs David McEr­lane from Lon­za as bi­o­log­ics lead

Last year
People
Manufacturing

MRM open to part­ner­ships af­ter lead can­di­date im­press­es in PhI­Ia ul­cer­a­tive col­i­tis tri­al

Last year
R&D

Re­Code rais­es an­oth­er $50M; His­to­gen halts clin­i­cal de­vel­op­ment; 60 De­grees with­draws Covid-19 IND

Last year
News Briefing

Al­phaFold, meet Al­phaMis­sense: Google Deep­Mind's AI suc­ces­sor pre­dicts how 71M mu­ta­tions cause dis­ease

Last year
AI

RNA edit­ing start­up launch­es with $30M based on Stan­ford and Uni­ver­si­ty of Tübin­gen re­search

Last year
Financing
Startups

With co­va­lent meds abuzz, RA Cap­i­tal and No­var­tis lead $56M seed round for new start­up

Last year
Financing
Startups

Kin­nate lays off 70% of em­ploy­ees, shaves pipeline to fo­cus on CDK4 and pan-RAF in­hibitor

Last year
People
R&D

No­var­tis hands back PD-1 in­hibitor to BeiGene af­ter reg­u­la­to­ry hur­dles

Last year
Deals
R&D

Stu­art Schreiber start­up launch­es with $50M to take mol­e­c­u­lar glue med­i­cines be­yond pro­tein degra­da­tion

Last year
Financing

Ex­clu­sive: Backed by for­mer Google CEO’s VC, a Col­orado biotech hatch­es plat­form to evolve de­graders

Last year
Financing
Startups

Iver­ic, Astel­las eye US la­bel ex­pan­sion for ge­o­graph­ic at­ro­phy drug af­ter pos­i­tive two-year da­ta

Last year
R&D
Pharma

FDA of­fers more guid­ance on re­ly­ing on just one tri­al and con­fir­ma­to­ry ev­i­dence for a new drug ap­proval

Last year
FDA+

Mer­ck’s women’s health spin­off Organon looks for phar­ma­ceu­ti­cals, di­ag­nos­tics, de­vices to fill out its pipeline

Last year
People
Pharma

As­traZeneca rolls up car­dio­vas­cu­lar, re­nal and meta­bol­ic in­ter­con­nec­tions in film and dig­i­tal ef­fort

Last year
Pharma
Marketing

AARP and non­prof­its ar­gue Medicare price ne­go­ti­a­tions are 'im­per­a­tive' to se­niors

Last year
Pharma
Law

CDER di­rec­tor urges man­u­fac­tur­ers to work with FDA to fix in­spec­tion is­sues be­fore shut­ting down

Last year
Pharma
FDA+

For­mer Alex­ion VP pleads guilty to in­sid­er trad­ing on Por­to­la buy­out

Last year
People
Law

Plat­form des­ig­na­tions: FDA's new cell and gene ther­a­py su­per of­fice di­rec­tor sees po­ten­tial

Last year
Cell/Gene Tx
FDA+

Ex­clu­sive: GSK re­vamps its re­search strat­e­gy, build­ing three teams to tar­get spe­cif­ic dis­ease spaces

Last year
People
R&D

CD­MOs Nephron and Can­ton each raise hun­dreds of mil­lions in fi­nanc­ing

Last year
Financing
Manufacturing
First page Previous page 278279280281282283284 Next page Last page
A service from the Financial Times